What is Excision BioTherapeutics?
Excision BioTherapeutics is a San Francisco-based biotechnology firm specializing in the development of CRISPR-based therapies designed to excise viral genomes from infected individuals. Unlike traditional treatments that manage symptoms, the company's core value proposition lies in its potential to provide functional cures for chronic viral diseases. By utilizing advanced gene-editing techniques, Excision is pioneering a new paradigm in infectious disease management, positioning itself as a high-growth entity within the competitive life sciences landscape. The company's strategic focus on precision medicine and its robust intellectual property portfolio distinguish it as a leader in the next generation of therapeutic innovation.
How much funding has Excision BioTherapeutics raised?
Excision BioTherapeutics has raised a total of $70M across 2 funding rounds:
Angel/Seed
$10M
Other Financing Round
$60M
Angel/Seed (2017): $10M with participation from ARTIS Ventures
Other Financing Round (2021): $60M led by Anzu Partners, Loreda Holdings, Olive Tree Capital, WRVI Capital, IndusAge Advisors, GreatPoint Energy, ARTIS Ventures, Cota Capital, Norwest Venture Partners, and Adjuvant Capital
Key Investors in Excision BioTherapeutics
ARTIS Ventures
A dedicated venture capital fund focused on Tech Bio and Health, investing in data-driven life sciences companies that leverage AI and engineering to enhance human wellness.
Anzu Partners
An investment firm managing $1 billion in assets, specializing in breakthrough technologies across the clean tech, industrial, and life sciences sectors.
Cota Capital
An investment firm that combines financial backing with deep operational expertise to support early-stage technology companies in the enterprise sector.
What's next for Excision BioTherapeutics?
With the recent strategic investment, Excision BioTherapeutics is well-positioned to transition from early-stage research into more advanced clinical development phases. The company's roadmap likely includes expanding its internal R&D capabilities, refining its CRISPR delivery mechanisms, and navigating the regulatory pathways necessary for human clinical trials. As the firm continues to scale, it will likely focus on strengthening its partnerships with global health organizations and enhancing its manufacturing processes to ensure the scalability of its curative solutions. The ongoing support from a diverse syndicate of venture capital firms provides the necessary runway to sustain long-term innovation and maintain its competitive edge in the rapidly evolving gene-editing market.
See full Excision BioTherapeutics company page
